Fresenius SE & Co. KGaA (FRE.F)
Frankfurt · EUR · Healthcare · Medical Care Facilities
€46.31 (+0.76%) as of
Key statistics
- Market cap
- 26.08B
- P/E (TTM)
- 16.72
- Forward P/E
- 11.75
- EPS (TTM)
- 2.77
- Dividend yield
- 2.28%
- 52-week range
- 35.19 – 52.84
- Beta
- 0.82
- Revenue (TTM)
- 23.28B
- Profit margin
- 6.54%
- Analyst target
- €55.98
- Volume
- 2.03k
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Headquarters
- Bad Homburg vor der Höhe, Germany
- Employees
- 178,486
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.